Efficacy and safety of ACEI plus tanshinone for acute exacerbation of pulmonary heart disease: a meta-analysis  

ACEI联合丹参酮治疗肺心病急性加重期的疗效和安全性的meta分析

作　　者：Min Li Lulu Chang Xiangfeng Yue Shuzhang Du 李敏;常路路;岳向峰;杜书章(郑州大学第一附属医院药学部,河南郑州450052)

机构地区：[1]Department of Pharmacy,The First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,Henan,China

出　　处：《Journal of Chinese Pharmaceutical Sciences》2022年第11期853-865,共13页中国药学（英文版）

基　　金：Health Commission of Henan Province (Grant No. LHGJ20190278)。

摘　　要：Acute exacerbation of pulmonary heart disease(AECPHD) is life-threatening. Conventional therapy plus angiotensinconverting enzyme inhibitors(ACEI) is not always practical. Recent trials have suggested the beneficial effects of the combination of ACEI and tanshinone on AECPHD. In the present study, we aimed to evaluate its efficacy and safety by meta-analysis systematically. The result indicated that combination of ACEI and tanshinone was more effective than ACEI monotherapy in AECPHD, as represented by treatment efficiency and mean pulmonary arterial pressure, PaCO_(2), and PaO_(2). However, the incidence of adverse events of combined therapy was higher than the control group, while the result of the analysis for adverse events was unstable. Further large-scale, multicenter, and rigorously designed randomized controlled trials(RCT) are needed to evaluate the efficacy and safety of combined therapy.肺心病急性加重(AECPHD)危及生命,常规治疗加ACEI并不理想。研究表明,血管紧张素转换酶抑制剂(ACEI)和丹参酮联合应用可控制AECPHD,但有效性和安全性始终未被系统性评价。本文旨在运用meta分析对其有效性、安全性进行系统性的评价。结果表明, ACEI联合丹参酮的有效性高于ACEI单用AECPD,表现为总体有效率增加,平均肺动脉压下降、二氧化碳分压下降、氧分压升高。联合治疗组不良事件发生率高于对照组,但结果不稳定。需要进一步的大规模、多中心随机对照试验(RCT)来研究联合治疗的安全性。

关 键 词：ENALAPRIL CAPTOPRIL TANSHINONE META-ANALYSIS AECPHD 

分 类 号：R951[医药卫生—药学]